Uncategorized

Nectin Therapeutics Advances Ongoing Clinical Trial and Expands Sites to Israel

Nectin Therapeutics Ltd. announced that it has progressed its Phase 1 clinical trial of NTX1088 to include a combination therapy arm with the immune-oncology drug KEYTRUDA®, MSD’s anti-PD-1 therapy, and expanded the trial to four additional global sites to include Sheba Medical Center, Hadassah Medical Center, Ochsner Health, and City of Hope along with flagship

Nectin Therapeutics Advances Ongoing Clinical Trial and Expands Sites to Israel Read More »

Madryn Asset Management Releases Evidence That SomaLogic Ran a Flawed and Incomplete Review of Alternatives

Madryn Asset Management, LP, a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc., disclosed that the Transaction Committee of the Company’s Board of Directors did not pursue a substantive dialogue with Laboratory Corporation of America Holdings – one of the industry’s most logical strategics, with a $19 billion market capitalization –

Madryn Asset Management Releases Evidence That SomaLogic Ran a Flawed and Incomplete Review of Alternatives Read More »

Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection

Senhwa Biosciences, Inc. announced that Taiwan Food and Drug Administration has approved its Phase II IND application of Silmitasertib to treat patients with community-acquired pneumonia caused by viral infection.

Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia (CAP) Associated with Viral Infection Read More »

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

Jemincare announced that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., recently received 6 approvals of clinical trials for its innovative drugs in the field of cancer, kidney and anti-infectious diseases, including 4 approvals from National Medical Products Administration and 2 approvals from the U.S. Food & Drug Administration.

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs Read More »

Scroll to Top